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Neonates have an immature immune system, which cannot adequately protect against
infectious diseases. Early in life, immune protection is accomplished by maternal antibod-
ies transferred from mother to offspring. However, decaying maternal antibodies inhibit
vaccination as is exemplified by the inhibition of seroconversion after measles vaccination.
This phenomenon has been described in both human and veterinary medicine and is inde-
pendent of the type of vaccine being used.This review will discuss the use of animal models
for vaccine research. I will review clinical solutions for inhibition of vaccination by maternal
antibodies, and the testing and development of potentially effective vaccines. These are
based on new mechanistic insight about the inhibitory mechanism of maternal antibodies.
Maternal antibodies inhibit the generation of antibodies whereas theT cell response is usu-
ally unaffected. B cell inhibition is mediated through a cross-link between B cell receptor
(BCR) with the Fcγ-receptor IIB by a vaccine–antibody complex. In animal experiments,
this inhibition can be partially overcome by injection of a vaccine-specific monoclonal IgM
antibody. IgM stimulates the B cell directly through cross-linking the BCR via complement
protein C3d and antigen to the complement receptor 2 (CR2) signaling complex. In addition,
it was shown that interferon alpha binds to the CD21 chain of CR2 as well as the interferon
receptor and that this dual receptor usage drives B cell responses in the presence of mater-
nal antibodies. In lieu of immunizing the infant, the concept of maternal immunization as
a strategy to protect neonates has been proposed. This approach would still not solve the
question of how to immunize in the presence of maternal antibodies but would defer the
time of infection to an age where infection might not have such a detrimental outcome as
in neonates. I will review successful examples and potential challenges of implementing
this concept.
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INTRODUCTION
Vaccination of neonates and infants is problematic because of two
unsolved problems: the immature immune system of neonates and
the presence of inhibitory maternal antibodies. A number of stud-
ies have determined that the immaturity of the immune system is
most pronounced after birth and is overcome as the child devel-
ops. The immaturity (inability to fully respond to an antigenic
stimulus) of the neonatal immune system has been observed in
humans (1) and a number of other species, e.g., pig (2), cow (3, 4),
and horse (5), and in experimental rodent models like mouse (1),
rat (6), and cotton rat (7, 8).
Maternal antibodies are transferred from mother to child and
protect neonates and infants during the time of maturation of
their immune system. The vast majority of maternal antibodies
are of the IgG isotype. In humans, maternal antibodies are pref-
erentially transferred before birth transplacentally, and in animals
of veterinary importance, preferentially through uptake of IgG in
the intestine from colostrum within the first 24 h after birth. These
passively acquired antibodies enter the bloodstream of offspring
and act as a protective shield throughout the body in the same way
as actively produced antibodies. Sometimes IgA antibodies con-
tained in breast milk are also referred to as maternal antibodies.
However, there are important differences in the action of passively
transferred IgG and IgA antibodies. Upon transfer after birth, IgG
antibodies are present in the bloodstream of the neonate in a finite
amount that declines over time. These IgG antibodies suppress
vaccine-induced immune responses. In contrast, IgA antibodies
are continuously supplied through breast milk from the mother
and protect the gastro-intestinal tract against pathogens without
having an effect on the immune response. For the purpose of this
review, the term “maternal antibodies” will be used for passively
transferred IgG antibodies.
Maternal antibodies are very effective in protecting neonates
and infants against most infectious diseases. The most impressive
example is the protection of children with agammaglobulinemia
(deficiency in the production of antibody) against bacterial infec-
tion for up to 6 months (9). Other documented examples of the
ability of maternal antibodies to fully or partially protect are the
amelioration of infection with respiratory syncytial virus (RSV)
(10) or influenza virus (11) in humans, canine distemper virus in
www.frontiersin.org September 2014 | Volume 5 | Article 446 | 1
Niewiesk Maternal antibodies
dogs (12), and infection with avian leukosis virus in chickens (13).
Over time, maternal antibody titers decline because antibodies are
being metabolized and do not protect any longer. However, even
low, non-protective titers of maternal antibodies are still able to
inhibit vaccination against infectious diseases of humans and ani-
mals. It is this phase of decaying maternal antibodies that presents
a window of opportunity for infection by pathogens encountering
the neonatal child or animal.
INHIBITION OF VACCINATION BY MATERNAL ANTIBODIES
In humans, maternal antibodies wane over a period of 6–
12 months (14–17). The kinetics of maternal antibody decline
is correlated to the amount of maternal antibody present in the
neonate after birth in that higher titers persist for a longer time. In
contrast to humans, the duration of maternal antibodies in agri-
culturally important animal species is usually 3–6 months (18–20)
and in chicken only 4–7 days (21). In contrast, maternal antibod-
ies in bats persist similar to humans for 6–12 months (22–24).
Maternal antibodies in all species have been reported to reduce
or abolish antibody generation after vaccination. The reduction
or lack of antibody typically results in reduced or absence of pro-
tection against disease (Tables 1 and 2). It is of interest to note
that all types of vaccines (live-attenuated, inactivated, subunit,
and experimental vaccines) have been reported to be inhibited.
For a number of experimental vaccines immunization with vari-
able success in the presence of maternal antibodies has been
reported but these reports have to be evaluated based on criteria
set out in Section “Evaluation and Development of Experimental
Vaccines.”
EXAMPLE: INHIBITION OF MEASLES VACCINATION BY
MATERNAL ANTIBODIES
The best studied example in human and veterinary medicine for
the inhibition of vaccination by maternal antibody is measles
vaccination. The measles vaccine virus (Edmonston strain) was
developed in the late 1950s and early 1960s by attenuating a wild
type virus on human and chicken embryo fibroblasts [for review
see Ref. (62)]. Today various derivatives of the Edmonston strain
are used as vaccine viruses worldwide (63). Immunization by both
the standard subcutaneous and more experimental respiratory
routes has been successful in protecting seronegative children (64).
The protective immune response induced by vaccination consists
of neutralizing antibodies against the two glycoproteins, with the
(receptor-binding) hemagglutinin protein being the major target
and the fusion protein the minor one (65). In addition, CD4 as
well as CD8 T cell responses are induced. Case reports describ-
ing persistent MV infection in T cell deficient patients support the
notion that T cells are required to clear infection but do not protect
against infection (66). This role of CD8 T cells in virus clearance
has been confirmed in the Rhesus macaques model (67). In cotton
rats, CD4 T cells have no role in protecting or clearing virus from
the respiratory tract (68). However, in mice they have a role in
clearing virus infection from brain tissue through production of
IFNγ (69, 70).
During their first year of life, children are protected by neu-
tralizing maternal antibodies against MV infection. Over time,
these antibody titers wane and eventually do not protect against
Table 1 | Inhibition of seroconversion of human vaccines by maternal
antibodies.
Infectious agent Type of vaccine Reference
Tetanus Combination protein vaccine (25)
Pneumococcus Combination protein vaccine (25, 26)
Hib Combination protein vaccine (25, 27)
Pertussis Combination protein vaccine (25)
Acellular and whole-cell vaccine (28)
Measles virus Live-attenuated (29–31)
Mumps virus Live-attenuated (32)
Hepatitis A virus Inactivated virus (33)
Hepatitis B virus Protein vaccine (34)
Rotavirus Live-attenuated (35)
Poliovirus Inactivated virus (36, 37)
Live-attenuated vaccine (38)
Influenza virus Cold recombinant influenza and
trivalent inactivated virus
(39)
This table lists examples of studies, which document the inhibition of or reduc-
tion in seroconversion after immunization with both live and non-live vaccines.
Jones et al. (25) document a stronger inhibitory effect of maternal antibodies on
tetanus and pneumococcal vaccines than Hib and pertussis vaccines. Most stud-
ies indicate that higher levels of maternal antibodies inhibit antibody development
more severely than low titers. Two studies (29, 35) indicate that an increase in
dose helps to improve antibody responses after immunization in the presence of
maternal antibodies.
wild type infection [for review see Ref. (71)]. Even these low,
non-protective antibody titers inhibit seroconversion after both
subcutaneous and intranasal immunization in cotton rats as well
as humans. The lack of seroconversion severely reduces protection
after vaccination with the live-attenuated vaccine virus. In the cot-
ton rat model, this leads to a complete lack of protection (68). In
clinical studies, immunization in the presence of maternal anti-
bodies leads to partial reduction in mortality (72) and morbidity
(73) (even in seronegative children). However, a broad clinically
desirable protective immunity (protective T and B cell responses,
and no clinical symptoms after infection rather then reduction in
morbidity and mortality) is not established after immunization in
the presence of maternal antibodies.
In contrast to the antibody response, MV-specific T cell prolif-
eration is usually measurable after immunization in the presence
of maternal antibodies (74–76). In spite of the inhibition of sero-
conversion, it was observed that vaccination in the presence of
maternal antibodies leads to priming of B cells. Although no anti-
bodies were produced, children immunized with measles vaccine
in the presence of maternal antibodies responded with a higher
immune response to booster vaccination after maternal antibodies
had declined than children who had not been vaccinated at all (77).
This study indicated that inhibition of B cell responses by mater-
nal antibodies is a temporary effect and not due to the induction
of anergy. However, it has also been observed that in children who
were immunized in the presence of maternal antibodies long term
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Table 2 | Inhibition of seroconversion of veterinary vaccines by
maternal antibodies.
Species Infectious disease Type of vaccine Reference
Dog Canine parvovirus Live-attenuated (40, 41)
Canine distemper virus Live-attenuated (42, 43)
Cat Feline panleukopenia
virus
Live-attenuated (44, 45)
Feline herpesvirus 1 Inactivated virus (44)
Feline calicivirus Inactivated virus (44)
Cow Bovine viral diarrhea
virus
Live-attenuated (46, 47)
Foot and mouth
disease virus
Inactivated virus (48)
Bovine respiratory
syncytial virus
Live-attenuated (49–51)
Pig Erysipelothrix
rhusiopathiae
Live-attenuated (52)
Pseudorabies virus Genetically attenuated (53)
Classical swine fever
virus
Protein vaccine (54, 55)
Live-attenuated
Influenza virus Protein vaccine (56)
Chicken Influenza virus Inactivated virus (57)
Raccoon Rabies virus Vaccinia virus expressing
rabies glycoprotein
(58)
Canine distemper virus Live-attenuated (59)
Wolves Canine distemper virus Live-attenuated (60)
Ferrets Canine distemper virus Live-attenuated (61)
This table lists examples of studies, which document the inhibition of or reduc-
tion in seroconversion after immunization with both live and non-live vaccines in
different species. It also lists an example of a vaccine (against canine distemper
virus), which is inhibited in several species.Three studies (46, 51, 53), included in
their study T cell measurements and detected T cell responses after immuniza-
tion in the presence of maternal antibodies although the antibody response was
inhibited.
antibody titers were reduced (even after boosting) compared to
children who were seronegative at the time of immunization (76).
Since no current vaccine formulation is fully effective in the
presence of maternal antibodies, two approaches have been used
clinically to address the problem: one, the use of a high titer
vaccine, and the other, the determination of the earliest time
point possible for successful vaccination. The high titer vaccine
(>104.7 pfu) had a 10- to 50-fold higher viral titer than the normal
vaccine and induced some level of protection after immunization
in the presence of maternal antibodies (29, 78). However, the use of
this vaccine was associated with increased mortality (particularly
in females) (79–81), which was attributed to immune suppression
by the vaccine and its use was discontinued. A possible explanation
for higher mortality in girls might be that girls have been reported
to have lower maternal antibody titers (82) that were overwhelmed
by a higher vaccine virus dose.
In a second approach, children were immunized at different
times after birth (in the face of declining maternal antibodies).
These studies have shown that a low level of maternal antibody
correlates best with vaccination success. At the age of 6 months,
maternal antibody titers are still high enough to suppress sero-
conversion but at the age of 9 months vaccination campaigns are
relatively successful (31, 83). However, the complete disappear-
ance of antibody at the age of 12 months seems to be optimal for
immunization (32, 74, 84–86). Additional studies into the levels of
maternal antibodies demonstrated that strong regional differences
exist in that in a number of countries maternal antibodies might
have disappeared by 6 months of age, and sometimes immuniza-
tion at 4.5 months of age might be partially successful (87, 88).
Regional differences might be due to a number of factors such as
the exposure to wild type virus infection of mothers, which results
in higher antibody titers and higher transfer rates into children
than in vaccinated mothers (89). Maternal antibody levels in chil-
dren of vaccinated mothers are lower and decline earlier than in
children from naturally infected mothers.
CLINICAL RELEVANCE OF INHIBITION OF VACCINATION BY
MATERNAL ANTIBODIES AND PRACTICAL SOLUTIONS
Numerous reports detail the inhibition of antibody responses after
vaccination in the presence of maternal antibodies. The important
question is whether this is clinically relevant and whether clin-
ical solutions exist to overcome the problem. For measles virus
vaccination, maternal antibodies clearly inhibit the generation of
neutralizing antibodies and therefore severely restrict protective
immunity. However, the clinical outcome might vary depend-
ing on the specific vaccine and infectious disease under study.
A recent study found that suppression of antibody responses
against the tetanus and pneumococcal vaccines was more pro-
nounced than against hemophilus influenza B and pertussis vac-
cines (25). Theoretically, immunization should be successful when
maternal antibodies have declined below the threshold of detec-
tion. In practice, it is not feasible to accurately predict this time
point as it depends on the amount of maternal antibody trans-
ferred, region, gender, nutritional status, and species. Therefore,
the measurement of antibody levels would be required before
immunization, which is not feasible in a clinical setting. The
clinical practice to immunize children and animals repeatedly
because most immunizations are based on a prime-boost prin-
ciple, also ensures that children and animals are immunized when
maternal antibodies have been metabolized. Immunization in the
presence of maternal antibodies does not interfere with later vac-
cinations, and this practice ensures that eventually the individual
is immunized when maternal antibodies have disappeared. How-
ever, a variable period of time without active immune protection
will remain and therefore this vaccination schedule is most suc-
cessful in regions with a low prevalence of infection. The other
important question for vaccination is whether antibodies or T
cells are a correlate of protection. If T cells play a major role
in protection [e.g., Aujeszky virus (90)], early immunization will
afford protection because the T cell response is affected very lit-
tle by maternal antibodies. If, in contrast, neutralizing antibodies
are required for protection, early immunization is not likely to
succeed.
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TYPE OF PLACENTA DETERMINES MODE OF TRANSFER OF
MATERNAL ANTIBODIES
The transfer of maternal antibodies from mother to offspring may
occur during pregnancy (from the maternal blood via transpla-
cental transfer) and within 24 h after birth (from colostrum via
the small intestine). The amount of antibody transferred by these
two mechanisms differs by species depending on the type of pla-
centa (http://placentation.ucsd.edu/placenta.html). Just prior to
formation of the placenta, there are a total of six layers of tissue
separating maternal and fetal blood. There are three layers of fetal
extraembryonic membranes in the chorioallantoic placenta of all
mammals, all of which are components of the mature placenta:
endothelium lining allantoic capillaries, connective tissue in the
form of chorioallantoic mesoderm, and the chorionic epithelium,
the outermost layer of fetal membranes derived from trophoblasts.
There are also three layers on the maternal side, but the number of
these layers that are retained – that is, not destroyed in the process
of placentation – varies greatly among species (see Table 3). Over-
all, species with few layers between maternal and fetal blood have
a higher rate of transport of maternal antibodies transplacentally
[through Fc-receptors (FcR)]. In species with more layers between
maternal and fetal blood, the transport of maternal antibodies
preferentially occurs through colostrum. Although the differences
between species are important for the study of placentation and
transfer of nutrients, for the study of vaccination in the presence
of maternal antibodies the structure of the placenta and the mode
of transmission of IgG is only relevant if intrapartum studies are
performed. Most studies, however, assess the inhibition of vacci-
nation sometime after birth and the relevant parameter in these
experimental settings is the amount of IgG being transferred to
the offspring.
EXPERIMENTAL MODELS TO STUDY THE EFFECT OF
HOMOLOGOUS VERSUS HETEROLOGOUS PASSIVELY
TRANSFERRED ANTIBODIES ON VACCINATION
Inhibition of vaccination has been studied in the presence of nat-
ural maternal antibodies or in the presence of passively transferred
homologous or heterologous antibodies. Overall, inhibition of
seroconversion after vaccination has been similar using both meth-
ods. For the induction of natural maternal antibodies, dams are
immunized during pairing with the male and will transfer mater-
nal antibodies to the pups. In rodents, differences can be found
in antibody levels between pups of the same litter, which may
occur because of the suckling hierarchy. The supposed advantage
of natural maternal antibodies is the fact that antibodies from the
same species have a predetermined fit for the FcR present in the
Table 3 |Type of placenta is species specific and determines route of transfer of maternal antibodies.
Species Placenta Maternal antibody
transfer
Transfer mediated by
neonatal Fc receptor (FcRn)
Reference
Human Hemochorial Transplacental Yes; preferential transport of
IgG1> IgG3> IgG4> IgG2
(91–94)
Rodents Hemochorial Transplacental/colostrum Yes (6, 95–98).
Mouse
Rat
Cotton rat Hemochorial Transplacental/colostrum Unknown (99, 100)
Dogs and cats Endotheliochorial Low transplacental/high
in colostrum
Unknown (12, 20, 40, 101–104)
Cattle, sheep,
pigs, and horses
Epitheliochorial Colostrum FcRn present in pig intestine,
role in IgG transfer questionable
(94, 105–107)
Birds None In ovo FcRY (bird equivalent to FcRn) (108, 109)
The three potential maternal layers in a placenta are the endothelium lining of endometrial blood vessels, connective tissue of the endometrium, and endometrial
epithelial cells. In humans and rodents, the fetal chorionic epithelium is in direct contact with maternal blood because only the maternal endothelium remains (hemo-
chorial placenta). In contrast, the chorionic epithelium of horse and pig fetuses remains separated from maternal blood by three layers of tissue (epitheliochorial
placenta) whereas only two layers remain in dogs and cats (endotheliochorial placenta). The fewer the layers between maternal and fetal blood the higher the rate
of transport of maternal antibodies transplacentally. In humans, the majority of maternal IgG is transferred via the placenta. The transfer is an active process during
which IgG binds to the neonatal Fc receptor (FcRn), which is located in the placental syncytiotrophoblast.The binding between FcRn and IgG is 100-fold higher at pH 6
than at pH 7.4 (91, 92). After endocytosis of IgG by the placental syncytiotrophoblast IgG binds to FcRn in the endosome at low pH, is transported to the opposite cell
membrane and released at physiological pH into the blood stream [reviewed by Palmeira et al. (110)].This mechanism explains why maternal antibodies are of the IgG
isotype. In contrast to this specific transport mechanism, it seems that in agricultural species IgG and other macromolecules are transported from colostrum across
the intestinal barrier in a non-specific fashion (111, 112). Within 24-h after birth, the intestine becomes impermeable to macromolecules and IgG transfer ceases.
Similar to rodents, e.g., pig intestinal epithelial cells also express FcRn during the neonatal period but it has been argued that the large amount of IgG taken up within
24 h is not consistent with receptor-mediated transport [discussed in Ref. (107)]. In contrast to rodents, pig FcRN also is expressed in the adult period of life (106) and
this expression pattern is not correlated with transfer of maternal antibody. In contrast to mammals, birds generate IgY antibodies instead of IgG antibodies and use
the IgY Fc-receptor (FcRY) to transport IgY into the egg.
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species whereas heterologous IgG does not always interact with
FcR (113, 114). However, studies in mice and humans have shown
that subclasses of homologous IgG differ in their interaction with
FcR (115, 116).
Often, the question of inhibition of vaccination by maternal
antibodies will have to be separated from the immaturity of the
neonatal immune system experimentally. One possible resolution
is the transfer of homologous immune serum into adolescent ani-
mals (117). Using this experimental model, it was shown that sup-
pression of vaccine responses correlates with amount of antibody
present at the time of immunization (118). The injection of anti-
bodies allows us to determine the amount of antibody transferred
and ensures equal titers in all animals of the experimental group.
In addition, often higher titers of passively transferred antibody
can be achieved than would be possible through the induction of
natural maternal antibodies. A disadvantage of homologous anti-
bodies (whether natural maternal antibodies or passively trans-
ferred) is that they are indistinguishable from antibodies induced
actively via immunization. The transfer of heterologous antibodies
provides the advantage that actively induced and passively trans-
ferred antibodies can be distinguished by ELISA. Heterologous
antibodies degrade faster than homologous antibodies, and e.g.,
in the cotton rat model the half-life of cotton rat IgG was estimated
to be 7 days versus a half-life of 3.5 days for injected human IgG
(Niewiesk, unpublished). The rate of decay should not matter for
vaccination studies, as the amount of antibody at the time of vac-
cination is important for inhibition, not the duration of antibody
levels. However, one should not inject heterologous antibodies
repeatedly, as that will lead to the induction of regulatory T cells,
which might interfere with the immune response after vaccination
(119). Another caveat is warranted when monoclonal antibodies
are used. It is important to test whether specific subclasses will
interact with the FcγRIIB receptor in the respective species and
be able to suppress B cell responses. In cotton rats, for example,
mouse IgG1 antibodies do not bind to the FcγIIB receptor and do
not interfere with vaccination whereas mouse IgG2a antibodies
do (114).
MECHANISMS OF INHIBITION OF VACCINATION BY
MATERNAL ANTIBODIES
ANTIBODY FEEDBACK MECHANISM
Since studies to address the mechanism of inhibition of serocon-
version after vaccination in the presence of maternal antibodies
have been rare, data from antibody feedback regulation have been
used to provide mechanistic insight into B cell inhibition by anti-
body. Antibody feedback regulation is the phenomenon whereby
co-injection of an antigen [usually sheep red blood cells (SRBC)]
and a monoclonal antibody specific for this particular antigen into
a naive mouse leads to a reduction or inhibition in the generation
of antigen-specific antibodies. [It is important to note that this
phenomenon is true for large particulate antigens like SRBC and
keyhole limpet hemocyanin (KLH)]. The suppression increases
with the amount and affinity of antibody given (120, 121) but is
independent of the IgG isotype (120, 121). In contrast to the B cell
response, a T helper cell response is not inhibited (122). More-
over, a recall response can be induced after the decline of passively
transferred antibody. Two major hypotheses might explain this
phenomenon: epitope masking and B cell regulation through the
Fcγ-receptor IIB (FcγRIIB).
Inhibition of B cell responses through epitope masking
Sheep red blood cell-specific antibodies recognize very few highly
repetitive epitopes on SRBC. The theory of epitope masking pos-
tulates that antibodies can cover these epitopes and mask them
from B cell recognition if enough antibody is used. Originally, it
was thought that all epitopes have to be covered by antibodies
to prohibit recognition by B cells (epitope-specific suppression).
However, it was shown that a monoclonal antibody against one
epitope can suppress recognition of a whole particulate antigen
by B cells (epitope unspecific suppression) (120, 121, 123). It has
been argued that at high antibody concentrations, steric hindrance
might explain this form of suppression. But even low antibody
concentrations of 0.4µg (corresponding to 2× 106 antibody mol-
ecules) are able to suppress antibody responses against 108 SRBC
(124). Epitope masking as a mechanism of suppression has always
been discussed in conjunction with a competing mechanism, the
regulation of B cells through the FcγRIIB.
Inhibition of B cell responses by binding of IgG to the Fcγ-receptor
IIB
B cells express the FcγRIIB as the only Fcγ receptor on their
surface. It has been shown in vitro that IgG specific for the B
cell receptor (BCR) binds to the BCR via its antigen binding
domain in the variable region and to FcγRIIB through the constant
region. Through the cross-linkage between BCR and FcγRIIB, the
tyrosine-based inhibitory motif of FcγRIIB is in close proximity
to the tyrosine-based activation motif of the BCR. This proximity
leads to inhibition of antigen-specific B cell activation. In vitro,
SRBC-specific B cells from spleens of immunized mice can be
activated by addition of SRBC to secrete antibody, which can be
detected using an ELISPOT system. This activation can be inhib-
ited by the addition of SRBC-specific IgG (124), which forms a
complex with SBRC and links the BCR to FcγRIIB. In contrast,
the F(ab′)2 fragment, which lacks the constant region (Fc) of IgG,
cannot cross-link these receptors and inhibit B cell stimulation.
Similarly, mouse B cells with a deletion in the gene coding for the
γ chain of the FcγRIIB cannot be inhibited by SRBC-specific IgG
(124). These in vitro data strongly argue for a role of FcγRIIB in
down-regulating B cell responses. In contrast, data obtained in vivo
do not unequivocally support the ability of IgG to suppress B cell
responses by FcγRIIB binding. In support of this mechanism are
data demonstrating that glycosylation of the constant region (Fc),
which is crucial for binding of IgG to the inhibitory FcγRIIB, is
necessary for inhibition (125, 126). In addition, some studies have
shown that F(ab′)2 fragments, in contrast to complete IgG, do not
inhibit antigen-specific responses (120, 127, 128). However, other
studies found little difference between F(ab′)2 fragments and com-
plete IgG (120, 127, 128), and in mice with a genetically deleted
FcγRIIB (and also deletion of FcγRI and FcγRIII) inhibition still
could be induced by IgG (124). Two technical comments must
be made in regard to the latter studies. After pepsin digestion,
the quality of the F(ab′)2 fragments varies and was not rigorously
controlled in these studies. In the study using genetically mod-
ified mice, the deletion of the common γ-chain (FcRγ) leads to
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the absence of FcγRI, FcγRIIB, and FcγRIII. In consequence, these
mice displayed a wide array of immunological abnormalities that
were not restricted to the B cell compartment (124). After anti-
gen injection, these mice generated a markedly stronger antibody
response indicating the lack of a feedback mechanism to regulate
B cell responses and antibody titers.
Stimulation of B cell responses by the binding of IgM to the
CD21/CD19/CD81/Leu-13 signaling complex
In the study of antibody feedback regulation, it was found that
co-injection of antigen and antigen-specific IgM increases anti-
body responses in the presence of an inhibitory IgG (125). These
data suggest that the inhibitory signal through FcγRIIB can be
overcome by stimulating signals via the complement receptor 2
(CR2) (CD21/CD19/CD81/Leu-13) complex. In vitro, a complex
of antigen, IgM and complement protein C3d cross-links the BCR
and CR2 and leads to B cell activation (129, 130). C3d which binds
to CD21 is produced through the activation of the classical com-
plement pathway involving the C2 and C4 complement proteins.
In mice, the cross-linkage increases the responsiveness of B cells
in the presence of antigen-specific IgM and antigen by two orders
of magnitude in comparison to antigen alone (131). This immune
enhancement by IgM is not seen in CD21 gene-targeted mice (132)
or mice in which complement was depleted prior to vaccination
(125) or in the absence of antigen. These data support a regulatory
role of IgG on B cell activation that can be overcome by stimulation
through IgM, and argues against simple epitope masking.
MECHANISM OF INHIBITION OF SEROCONVERSION AFTER
VACCINATION IN THE PRESENCE OF MATERNAL ANTIBODIES
In addition to mechanisms based on the work performed in the
antibody feedback mechanism model (epitope masking and B cell
inhibition through FcγRIIB), two additional mechanisms have
been hypothesized to play a role in inhibition of vaccination by
maternal antibodies: removal of vaccine antigen by macrophages
and neutralization of vaccine virus by maternal antibodies.
Antigen removal by macrophages
It has been assumed that macrophages remove antibody–virus
complexes from the circulation through binding to FcR to such
a degree as to abolish immune responses. There is no experi-
mental evidence to support this hypothesis, and it also does not
explain why the B cell response is preferentially inhibited whereas
a T cell response is consistently detected after immunization in
the presence of maternal antibodies. The only evidence that Fc-
receptor-mediated phagocytosis of antigen–antibody complexes
redirects the immune response is the finding in mice that it leads
to increased IL10 secretion (133). The increase in IL10 could direct
T cell responses toward a Th2 response, which, however, would
not lead to a decrease in antibody responses. So far, there has been
no evidence that the removal of antigen–antibody complexes by
macrophages influences antibody responses.
Neutralization of live-attenuated vaccine
An often-suggested explanation for the lack of vaccination suc-
cess in the presence of maternal antibodies is neutralization of the
vaccine virus, which would reduce the amount of viral antigen
below a certain (undefined) threshold and thereby interfere with
immune recognition. Three facts argue against this hypothesis:
maternal antibodies suppress not only replicating live-attenuated
vaccines but also (non-replicating) protein vaccines; immuniza-
tion with vector systems expressing measles virus proteins (which
are not sensitive to neutralizing antibodies) are inhibited by mater-
nal antibodies (134–136); and non-neutralizing antibodies block
vaccination with a live-attenuated vaccine (114).
B cell inhibition through epitope masking
The idea of epitope masking predicts that B cell epitopes on a
vaccine will be covered by antibody and therefore will not be rec-
ognized by B cells. In consequence, this effect is dependent on the
concentration of antibody present in the circulation, and should
be seen with both a complete IgG antibody and an IgG antibody
lacking its constant region [so-called F(ab)2 fragment]. However,
experimentally we could demonstrate that one antibody at a high
concentration is less efficient in inhibiting vaccination than three
antibodies at lower concentrations, and that only complete IgG
antibody can block vaccination (114). In addition, the inhibition
of antibody generation afterward was not specific to the epitope
recognized by the inhibitory antibody.
B cell inhibition through cross-link of BCR with FcγRIIB
In contrast to these results, which did not support epitope mask-
ing as a mechanism, the interaction between FcγRIIB and maternal
antibodies proved to be important. Both in vitro and in vivo, IgG
can block B cell responses whereas F(ab)2 fragments cannot. A
monoclonal antibody with an Fc region that does not bind to
cotton rat FcγRIIB cannot inhibit B cell responses (114). These
data support a mechanism of inhibition depending on complex
formation of the vaccine with IgG antibodies (114). This com-
plex cross-links the BCR (which recognizes the vaccine antigen)
to the FcγIIB receptor (which binds the Fc region of the IgG
antibody) on the surface of B cells. The cross-link results in a
negative signal that inhibits both the proliferation of B cells (137)
and the secretion of antibodies (114) (Figure 1A). In evolution-
ary terms, this mechanism developed to avoid an over-reactive B
cell response in order to conserve resources. If IgG antibodies are
already present in an organism after infection or vaccination, it
is not necessary to produce more antibodies. In essence, maternal
antibodies signal that there is no need to produce more antibod-
ies. In contrast to antibody production after an active immune
response, however, the passively transferred maternal antibod-
ies decline and the infant is left without an adequate B cell and
antibody response.
IgM stimulation of inhibited B cells
Further evidence in support of the regulatory model of B cell inhi-
bition is provided by the role of IgM in the stimulation of B cells
in vitro and in vivo. The negative feedback regulation of B cells
should function in children with similar IgG titers irrespective
of whether they have been actively immunized or have received
maternal antibodies. However, immunized children will gener-
ate additional antibodies after re-immunization whereas children
with maternal antibodies will not or at very low titers. This phe-
nomenon can (at least partially) be explained by the presence of
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FIGURE 1 | Model of B cell activation in the presence of maternal IgG.
B cells are being stimulated through three signals, the first one is recognition
of antigen by the B cell receptor (BCR), the second the interaction with T cells
through CD40/CD40 ligand, and the third cytokines like type I interferon or
IL-6. During vaccination in the presence of maternal antibodies T cell
responses are generated and therefore the second signal is provided. (A) In
the presence of maternal antibodies (IgG), the first signal is downregulated by
a cross-link between BCR and FcγRIIB. If MV-specific IgG binds to MV, the
constant region is bound by the receptor for the constant region (Fc) of IgG
(which is FcγRIIB). FcγRIIB is the only Fc-receptor on B cells and does not
bind other immunoglobulins like IgM or IgA. After juxtaposition of the BCR
and FcγRIIB, the tyrosine-based inhibitory motif of FcγRIIB is in close
proximity to the tyrosine-based activation motif of BCR and delivers a
negative signal. (B) If MV-specific IgM binds to MV, it also binds via C3d to
CD21 (complement receptor 2), which is part of the positively signaling
CD21/CD19/CD83/Leu-13 complex. The opsonin C3d does not bind to IgG.
(C) Interferon α (type I interferon) binds to both the interferon receptor and
CD21, and the dual receptor usage leads to a strong positive signal. It
stimulates antibody secretion by B cells in the presence of maternal
antibodies. (D) A possible approach to vaccination in the presence of maternal
antibodies is the reduction of the vaccine antigen into small units, which do
form antigen–antibody complexes unable to cross-link BCR and FcγRIIB. An
example of this approach is experimental vaccination against respiratory
syncytial virus in the presence of maternal antibodies (138).
IgM that is being generated after active immunization. IgM forms
a complex with the vaccine and a complement protein (C3d). This
complex cross-links the BCR with the CR2 on the surface of B cells
(Figure 1B). The cross-link results in activation of B cells in vitro
and can partially overcome the inhibition by the cross-link of the
BCR and CD32 in vivo (114). In consequence, some IgG antibody
is produced. The important component for the stimulatory effect
of CR2 is the CD21 chain that binds to C3d. This finding is con-
sistent with the model of B cell regulation but not with epitope
masking.
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Type I interferon induction stimulates B cells in the presence of
maternal antibodies
Another way to stimulate B cells experimentally in the presence
of maternal antibody is the induction of type I interferon. It has
been demonstrated that CD21 binds C3d and interferon alpha
with the same affinity (139) indicating that interferon alpha might
have a functional role in B cell stimulation. Indeed, interferon
alpha stimulation leads to the up-regulation of a number of B
cell genes in a human B cell line (140). In vivo, B cells use both
the interferon receptor and CD21 (which is a chain of the CR2)
as a functional interferon receptor to stimulate antibody secre-
tion (137) (Figure 1C). One way of inducing high levels of type
I interferon is the combined use of TLR-3 and TLR-9 agonists as
adjuvants for immunization. Because of the dual receptor usage,
the induction of type I interferon in vivo strongly stimulates B
cell responses and restores antibody levels after immunization in
the presence of maternal antibodies (137). This finding is con-
sistent with the model of FcγRIIB-mediated inhibition of B cell
regulation but not with epitope masking.
In neonates, immunization is not only impaired by the
inhibitory action of maternal antibodies, but also by the overall
immaturity of the immune system. The induction of type I inter-
feron stimulates immature B cells in neonatal cotton rats, even in
the presence of maternal antibodies (141).
Engagement of FcγRIIB is important for inhibition of B cells
Using the cotton rat model of measles virus vaccination (142), we
have shown that maternal antibodies inhibit B cells through com-
plex formation with the vaccine and cross-linking of the BCRs and
FcγRIIB (114). A mixture of antibodies recognizing three or more
epitopes was more inhibitory than one antibody at the same anti-
body concentration. These data support the current thinking that
oligomerization of FcγRIIBs is required for an inhibitory signal
interfering with B cell proliferation and antibody secretion (143).
However, for effective oligomerization not only the number of
different antibodies but also the size of an antigen seems to be
important. Passively transferred antibodies specific for di-nitro-
phenyl (DNP) groups inhibit immunization with DNP bound
to SRBC (4–5µm) but not immunization with DNP bound to
KLH (two subunits of 30 and 33 nm) (144, 145). Similarly, measles
virus, which is inhibited by maternal antibodies, is a large antigen
[250–450 nm (146)] with multiple epitopes on its surface [at least
13 for hemagglutinin (MV-H) and 6 for fusion protein (MV-F)]
(147). These data indicate that an antigen requires a certain size
to effectively cross-link (as antibody–antigen-complex) BCRs and
FcγRIIBs (Figure 1D). Consistent with this concept is a report that
immunization with a small polypeptide containing a neutralizing
B cell epitope escaped inhibition by maternal antibodies (138).
EVALUATION AND DEVELOPMENT OF EXPERIMENTAL
VACCINES
A number of studies claim vaccine efficacy after immunization in
the presence of maternal antibodies for both approved vaccines
and vaccine candidates. For experimental vaccines successes as
well as failures have been reported for a variety of vector systems
expressing the vaccine antigen simultaneously with or without dif-
ferent cytokine (combinations). The results from these studies are
contradictory and it helps to clearly define the experimental con-
ditions and study design. A vaccine can most easily be proven to
be successful if it is used in the presence of low titers of maternal
antibodies at the time of immunization, if T cell responses are
measured and if surrogate markers like histological changes (in
animal models) are used for protective efficacy. To prove convinc-
ingly vaccine efficacy in the presence of maternal antibodies, levels
of maternal antibodies at the time of vaccination have to be high,
neutralizing antibodies should be measured as an immunological
parameter, and protection should be measured as clinical efficacy
by the absence of clinical symptoms or a significant reduction in
viral/bacterial titers. By these standards, very few examples of suc-
cessful immunization in the presence of maternal antibodies exist,
thus necessitating further research into this area. When consider-
ing the development and testing of vaccines for immunization in
the presence of maternal antibodies, three options seem to emerge
as being potentially successful: inoculation at a site with low IgG,
continuous expression of antigen, and inoculation with adjuvants
stimulating type I interferon secretion. Inhibitory maternal anti-
bodies are of the IgG isotype, and IgG is present in respiratory
and ocular fluids and saliva (148, 149) although at lower con-
centrations than in the blood. Occasionally, vector systems have
been used successfully in animal model in the presence of mater-
nal antibodies when alternate routes of immunization (other than
subcutaneous or intramuscular) were used (134, 150–152). Exper-
imentally, this approach could be combined with measures of IgG
titers at the site of inoculation (e.g., mouth, eye, and nose) to cor-
relate vaccination success with lower antibody titers. The concept
of continuous expression of antigen is based on the finding that
repeated immunization leads to an antibody response in the pres-
ence of maternal antibodies. If a vector system can be found that
continuously expresses antigen, B cell responses should be stim-
ulated when antibody titers fall to very low levels. An example of
this concept is the expression of infectious bursitis virus (IBV)
proteins through an attenuated Marek’s diseases virus (MDV)
vector that persists in the chicken and leads to good immunity
(153) in the presence of maternal antibodies. The induction of
type I interferon is based on the ability of type I interferon to
drive B cell responses in tissue culture and in experimental sys-
tems in the presence of maternal antibodies. An example of this
concept is the immunization of pigs with adjuvants inducing type
I interferon (154).
INDUCTION OF MATERNAL ANTIBODIES THROUGH
MATERNAL IMMUNIZATION AS INDIRECT IMMUNIZATION
OF INFANTS
Because of their relative immunological immaturity, infants are
usually not immunized before the age of 2–3 months (depend-
ing on country-specific immunization schedules) with the most
common exception of neonatal BCG immunization in some coun-
tries. In order to provide protection earlier in life, two other
vaccination strategies have been discussed and/or used: cocooning
and maternal immunization. The method of cocooning relies on
immunization of all people in contact with the infant to mini-
mize the risk of pathogen transmission and infection. Although
this method can be effective it is sometimes difficult to imple-
ment. Another concept that has received more attention recently is
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maternal immunization. Maternal antibodies have been proposed
as a means of protecting the infant during a sensitive time in the
development of their immune system. If protective high levels of
maternal antibodies can be achieved in infants, they would be pro-
tected during the most immature phase of their immune system. In
addition, the young organism becomes better adapted to cope with
infectious diseases by improved non-immune host responses, e.g.,
faster regeneration of epithelial cells after gastro-intestinal infec-
tion. Maternal immunization has the added advantage that the
mother’s immune system is fully mature and will respond well to
vaccination, thus providing protection to the mother and high lev-
els of maternal antibodies to the infant. Based on the above named
studies about protective levels of maternal antibodies and their
kinetics of decline, it should theoretically be possible to induce
high levels of antibodies, which are protective for up to 6 months.
SUCCESSFUL EXAMPLES OF MATERNAL IMMUNIZATION
Currently, this concept is supported by data for vaccinations
against tetanus, influenza virus, and pertussis. In 1961, a seminal
study demonstrated the efficacy of maternal immunization with
tetanus toxoid in the prevention of neonatal tetanus and reduction
of neonatal mortality (155). Subsequently, the WHO Maternal–
Neonatal Tetanus (MNT) elimination program has resulted in the
reduction of neonatal death due to tetanus from about 787,000
death in the late 1980s to 59,000 death in 2008 (156). The final
goal of the WHO campaign is to eliminate MNT, with elimination
being defined at <1 case per 1000 live births.
Another case of successful maternal immunization is influenza
vaccination. Influenza virus infection is a serious problem for
pregnant women and immunization before, during, and after
pregnancy substantially reduces serious clinical outcomes of infec-
tion. In addition, studies have demonstrated a protective effect
on the child. Immunization of mothers leads to the increased
transmission of maternal antibodies (157, 158), a 41–63% reduc-
tion in laboratory confirmed cases of influenza virus infection
over a period of 6 months (159, 160), and a 39–91% reduction in
hospitalizations of newborns (11, 159).
In addition, immunization against pertussis with the acellu-
lar pertussis antigen vaccine has proven to increase the level of
maternal antibodies (161–163) and protect infants from clinical
pertussis (161). A meta-analysis of vaccination studies found that
cocooning (immunization of all direct contacts of an infant) and
maternal immunization significantly reduced clinical disease and
also were found to be cost–effective from a payer’s perspective
(164). It should be noted that in these three examples inactivated
vaccines were used. In principle, maternal immunization can be
applied to other (live-attenuated) vaccines and infectious diseases
as well. However, it has been reported that maternal immunization
with a pneumococcal (polysaccharide) vaccine does not protect
infants against clinical disease (165).
PRINCIPAL QUESTIONS SURROUNDING MATERNAL IMMUNIZATION
In order to study the effect of maternal immunization systemati-
cally, a number of questions have to be considered. For maternal
immunization to be effective, antibodies have to be the immuno-
logical correlate of protection for the specific infectious disease
and a specified level of protective titers has to be known as a target
parameter to have an appreciable effect on clinical outcome. The
main task is to determine the best time point and immunization
schedule to immunize the mother. There is little information in
the literature to guide immunization of mothers in order to obtain
the best transfer of maternal antibodies. Current guidelines target
immunizations of women with the goal to protect them and the
fetus during pregnancy, and are usually divided in immunizations
before and during pregnancy. In practical terms, mothers are often
being immunized only when they are pregnant and usually immu-
nization with inactivated rather than live-attenuated vaccines is
recommended. A number of studies has found that maternal anti-
body titers in the child are higher than in the serum of the mother
when these are low (83, 157) and lower than in the serum of the
mother if the mother had high levels of antibodies. The cut-off
seems to be a total IgG concentration of 15 g/L (166). This phe-
nomenon can be explained by the transport of IgG via the FcRn
receptor across the placental barrier. If the FcRn receptor mole-
cules are saturated, IgG will be degraded by lysosomal enzymes
inside the vesicles (167). However, transfer of antibodies does not
only depend on the total IgG concentration in the mother’s blood
but also on the isotype composition. The binding affinity of FcRn
is highest for IgG1, followed by IgG4, IgG3 and is weakest for IgG2
(110). In consequence, more IgG1 is transported transplacentally
than e.g., IgG2. This preferential transport mechanism explains
why antibodies against specific vaccines are transported more effi-
ciently than others. Usually, antibodies against T cell-dependent
antigens (proteins) are of the IgG1 isotype and are more efficiently
transported than antibodies against T cell-independent antigens
(polysaccharides) of the IgG2 isotype. Based on these consider-
ations, effective vaccines could be used to immunize expecting
mothers in order to protect the neonates and infants. However, it
is possible that for every vaccine a threshold of maternal antibody
titers can be defined that cannot be changed even with very effec-
tive vaccines. This hypothesis has to be addressed experimentally
in larger clinical studies.
Another factor influencing maternal antibody titers in chil-
dren is gestational age. IgG transfer from mother to child starts
at 13 weeks of age. However, in the third trimester the expres-
sion of FcRn receptors increases and subsequently the transfer
rate of maternal antibodies improves with the highest amount
of IgG (>50%) transferred during the last 4 weeks before birth
(168, 169). If relatively ineffective vaccines are available that do
not induce long-lasting antibody responses, immunization dur-
ing the third trimester of pregnancy might be an option. It has
been demonstrated that a not very effective vaccine like pertussis
might be beneficially applied during this time (170). An additional
consideration for maternal immunization is the nutritional status
of both mother and child. In general terms, nutrition influences
immune responses but has not been shown to influence the level
of antibody in the mother. However, it has been shown that under-
nourished children have lower maternal antibody titers, although
the underlying reason is currently unknown (171). Other factors
like maternal age, maternal weight, parity, and type of delivery do
not influence transplacental antibody transfer (172).
In contrast to humans, immunization of agricultural animals is
relatively straightforward as immunization schedules can be easily
applied to breeder animals at any time. Overall, the prevailing view
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is that the time of immunization is not relevant as long as mater-
nal antibody titers are high at birth because transfer occurs during
a short window after birth and seems to be solely dependent on
antibody titers in colostrum.
EXAMPLE: HOW CAN MATERNAL IMMUNIZATION WORK AGAINST
RESPIRATORY SYNCYTIAL VIRUS INFECTION?
In order to answer the question of whether maternal immuniza-
tion against a specific disease will lead to a reproducible and
protective increase in antibody titers in children, one has to con-
sider the total amount of IgG as well as the quality of antibody
being induced by immunization. To illustrate these questions, I
have chosen the example of immunization against RSV infection.
RSV infection leads to severe respiratory infections in adults and
is the second most common viral cause of death in the elderly
(after influenza virus) (173). RSV infection is also the leading
viral infection in lower respiratory disease in children, which is a
particular problem in preterm babies and in neonates in their
first months of life (174). So far, no vaccine or therapeutic is
available. The discussion currently centers on the question of
whether a vaccine could be developed that is safe and effective in
neonates. Because the result of immunization of neonates is still
elusive, an alternate suggestion is to use a to-be-developed vac-
cine to immunize mothers and provide protection for neonates
and infants through maternal antibodies during the first 6 months
of life. However, it is controversial as to whether maternal anti-
bodies have a beneficial effect against RSV infection. RSV-specific
antibodies are present in children during the first 6 months of
life and have an estimated half-life of 1.5 months. Some stud-
ies have observed a protective effect of maternal antibodies (10,
175) whereas some did not [for review see Ref. (176)]. Currently,
preterm infants (depending on their gestational age) are prophy-
lactically treated with a monoclonal antibody against RSV. This
prophylaxis is effective because the antibody has a high affin-
ity (177, 178). In contrast to this antibody, naturally generated
antibodies often have lower affinities resulting in lower neutraliz-
ing efficacy. In consequence, it will be important to induce high
affinity antibodies in mothers through vaccination. Neutraliz-
ing antibodies against RSV bind to the fusion protein (F) and
the glycoprotein (G). However, it has been demonstrated that
vaccination with a RSV lacking the G protein is able to pro-
tect against viral challenge (179) and most attention in terms
of vaccine development has been focused on the F protein. On
the surface of the virion the fusion protein is folded so that the
fusion peptide necessary to mediate fusion is protected from the
environment (pre-fusion F). Upon triggering, the fusion protein
unfolds and initiates fusion with the cellular membrane (post-
fusion F). Palivizumab, the antibody that prophylactically protects
children against RSV infection binds to both pre- and post-fusion
F. Recent publications have defined the structure of the pre- and
post-fusion F protein and have demonstrated that the most effec-
tive in vitro neutralizing antibodies bind to the pre-fusion F thus
leading to the assumption that the goal of vaccination has to be
the increase of antibody against pre-fusion F (180–182). Based on
this knowledge clinical studies should be devised that not only
take the total amount of antibody into account but also measure
the affinity of the antibody as well as its target (G protein and
pre- as well as post-fusion F protein). Antibodies are being trans-
ferred transplacentally based on their ability to bind FcRn and not
on their affinity to RSV, and this transfer seems to be saturable
depending on antibody level in the maternal blood. If a relatively
small proportion of antibody is of high affinity it might not be
possible to reach high protective levels of maternal antibodies.
Another concern is immunization in the presence of maternal anti-
bodies. As with other infectious diseases, it has been shown that
even low levels of maternal antibody inhibit RSV-specific B cell
and antibody responses (183, 184), a problem that will still exist
after increased transfer of maternal antibodies due to maternal
immunization.
SUMMARY AND OUTLOOK
Many examples exist that demonstrate the inhibition of both
human and veterinary vaccines by maternal antibodies. B cell inhi-
bition is mediated through a cross-link between the BCR with
the FcγRIIB by a vaccine–antibody complex. Knowledge of the
underlying mechanisms helps us to understand the possibilities
and limitations of our current clinical approaches and will help
in the development and testing of new vaccines. This knowledge
also will help us to evaluate and develop the concept of maternal
immunization as a mechanism to protect infants against common
infectious diseases. The potential benefit of maternal immuniza-
tion is protection of the mother and a delayed susceptibility to
infection of the child. However, by most estimates children will not
be protected for more than 6 months of life whereas full immuno-
logical maturity seems to be accomplished only after 12 months.
A final unanswered question about maternal immunization, how-
ever, is how to deal with immunization in the presence of maternal
antibodies. In consequence, the question of vaccinating in the
presence of maternal antibodies will remain and still has to be
resolved.
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